Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Details

vida: extract claims from 2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis

- Source: inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

2026-05-03 04:36:00 +00:00

1.3 KiB

Raw Blame History

NCT04199728: GLP-1 Receptor Agonist for Opioid Use Disorder

Type: Clinical trial
Phase: 2
Status: Active (as of April 2026)
Intervention: GLP-1 receptor agonist (specific drug not specified in source)
Target: Opioid Use Disorder (OUD)

Trial Context

Part of broader GLP-1 substance use disorder research program. As of April 2026, 4 OUD trials active out of 33 total SUD trials.

Evidence Base

Liraglutide OUD data:

~40% reduction in opioid craving in small randomized double-blind placebo-controlled residential study
Phase 2 evidence only

Semaglutide OUD data:

Significantly reduced opioid overdose risk in 1-year follow-up for patients with comorbid T2D + OUD (real-world observational data)
Cannot distinguish causal mechanism from selection effects

Mechanism: GLP-1 receptors in ventral tegmental area (VTA) and nucleus accumbens reduce dopamine surge from opioid exposure, attenuating reward salience.

Critical limitation: All human evidence from patients with comorbid metabolic disease. Efficacy for OUD without T2D/obesity comorbidity unknown and largely unstudied.

Timeline

2026-04-28 — NBC News synthesis reports Phase 2 evidence for GLP-1 in OUD, no Phase 3 trials completed

Sources

NBC News/Pharmacy Times synthesis, April 2026
ClinicalTrials.gov NCT04199728

1.3 KiB Raw Blame History